(Q37763502)

22 August 2017

1 reference

title

Metronomic chemotherapy: new rationale for new directions (English)

1 reference

22 August 2017

1 reference

2

Maria Kavallaris

1 reference

22 August 2017

Eddy Pasquier

1

1 reference

PubMed ID

20531380

22 August 2017

Nicolas André

series ordinal

3

1 reference

PubMed ID

20531380

22 August 2017

language of work or name

English

0 references

publication date

8 June 2010

1 reference

Nature Reviews Clinical Oncology

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

455-465

1 reference

22 August 2017

8

1 reference

Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer.

22 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Transplacental carcinogenesis by stilbestrol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Modes of resistance to anti-angiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Biomarkers of response and resistance to antiangiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

The anti-angiogenic basis of metronomic chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Metronomic scheduling: the future of chemotherapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Antiangiogenic metronomic chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

To widen the setting of cancer patients who could benefit from metronomic capecitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Oral metronomic cyclophosphamide in elderly with metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Systems biology: a therapeutic target for tumor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Secondary Ph+ acute lymphoblastic leukemia after temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Metronomic chemotherapy-induced bilateral subdural hematoma in a child with meningeal carcinomatosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Redefining the target: chemotherapeutics as antiangiogenics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Metronomic chemotherapy: an antiangiogenic scheduling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Cancer immunoediting: from immunosurveillance to tumor escape

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Immunological aspects of cancer chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

The significance of Treg cells in defective tumor immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Models, mechanisms and clinical evidence for cancer dormancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Tumor dormancy of primary and secondary cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Tumorigenesis and the angiogenic switch

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Circulating tumor cells in patients with breast cancer dormancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Tumor dormancy in vivo by prevention of neovascularization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Experimental retinal neovascularization induced by intravitreal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Survival of leukemic cells in a dormant state following cyclophosphamide-induced cure of strongly immunogenic mouse leukemia (DL811)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

T-cell immunity in the induction and maintenance of a tumour dormant state

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Stopping treatment can reverse acquired resistance to letrozole

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Molecular and cellular biomarkers for angiogenesis in clinical oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Nitric oxide acts on the mitochondria and protects human endothelial cells from apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Glioma-associated endothelial cells are chemoresistant to temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Cellular senescence: its role in tumor suppression and aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Kinetic analysis of regulatory events in G1 leading to proliferation or quiescence of Swiss 3T3 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

A new description of cellular quiescence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Natural selection: The evolution of cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Therapeutic targeting of apoptotic pathways in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Cancer as an evolutionary and ecological process

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

For cancer, seek and destroy or live and let live?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.82

Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis

31 March 2020

1 reference

12 December 2020

Tumor heterogeneity: causes and consequences

1 reference

12 December 2020

Tumor angiogenesis: therapeutic implications

1 reference

12 December 2020

Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study

1 reference

12 December 2020

Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts

1 reference

12 December 2020

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

1 reference

12 December 2020

Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.

1 reference

12 December 2020

The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer

1 reference

12 December 2020

A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.

1 reference

12 December 2020

Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors.

1 reference

12 December 2020

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

1 reference

12 December 2020

Tumor cell senescence in cancer treatment

1 reference

12 December 2020

Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.

1 reference

12 December 2020

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

12 December 2020

Prolonged tumor dormancy by prevention of neovascularization in the vitreous

1 reference

12 December 2020

10.1038/NRCLINONC.2010.82

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20531380